Sustained viral gene delivery from a micro-fibrous, elastomeric cardiac patch to the ischemic rat heart
Source abstract
Abstract
Biodegradable and elastomeric patches have been applied to the surface of infarcted hearts as temporary mechanical supports to effectively alter adverse left ventricular remodeling processes. In this report, recombinant adeno-associated virus (AAV), known for its persistent transgene expression and low pathogenicity, was incorporated into elastomeric polyester urethane urea (PEUU) and polyester ether urethane urea (PEEUU) and processed by electrospinning into two formats (solid fibers and core-sheath fibers) designed to influence the controlled release behavior. The extended release of AAV encoding green fluorescent protein (GFP) was assessed in vitro. Sustained and localized viral particle delivery was achieved over 2 months in vitro. The biodegradable cardiac patches with or without AAV-GFP were implanted over rat left ventricular lesions three days following myocardial infarction to evaluate the transduction effect of released viral vectors. AAV particles were directly injected into the infarcted hearts as a control. Cardiac function and remodeling were significantly improved for 12 weeks after patch implantation compared to AAV injection. More GFP genes was expressed in the AAV patch group than AAV injection group, with both α-SMA positive cells and cardiac troponin T positive cells transduced in the patch group. Overall, the extended release behavior, prolonged transgene expression, and elastomeric mechanical properties make the AAV-loaded scaffold an attractive option for cardiac tissue engineering where both gene delivery and appropriate mechanical support are desired.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cardiac Structural Anomalies and Repair · Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (79)
Show source-provided references
1. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications10.1161/01.CIR.81.4.1161 ↗
2. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges10.1016/j.actbio.2010.06.039 ↗
3. An elastic, biodegradable cardiac patch induces contractile smooth muscle and improves cardiac remodeling and function in subacute myocardial infarction10.1016/j.jacc.2007.02.050 ↗
4. Magovern · 2006 · 364
5. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery10.1016/j.jacc.2013.01.072 ↗
6. Stem cell therapy for the heart: blind alley or magic bullet?10.1007/s12265-016-9708-y ↗
7. Mechanical circulatory support: current status and future directions10.1016/j.pcad.2016.01.006 ↗
8. Biomaterials for stem cell culture and seeding for the generation and delivery of cardiac myocytes10.1097/MOT.0b013e32835a34a6 ↗
9. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation10.1093/cvr/cvv205 ↗
10. Advances in gene therapy for heart failure
11. Gene therapy for myocardial angiogenesis initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia10.1161/01.CIR.98.25.2800 ↗
12. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs10.1152/ajpheart.00636.2010 ↗
13. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium-and high-dose groups10.1007/s11033-009-9665-5 ↗
14. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris10.1161/hc1102.105595 ↗
15. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure10.1161/CIRCRESAHA.111.300440 ↗
16. Gene therapy for ischemic heart disease10.1517/14712598.2011.570749 ↗
17. Cardiovascular gene therapy for myocardial infarction10.1517/14712598.2014.866085 ↗
18. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors10.1016/j.cell.2010.07.002 ↗
19. Heart repair by reprogramming non-myocytes with cardiac transcription factors10.1038/nature11139 ↗
20. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes10.1038/nature11044 ↗
21. MicroRNAs and cardiac regeneration10.1161/CIRCRESAHA.116.304377 ↗
22. Efficient gene transfer into myocardium by direct injection of adenovirus vectors10.1161/01.RES.73.6.1202 ↗
23. Viral and nonviral delivery systems for gene delivery10.4103/2277-9175.98152 ↗
24. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial10.1016/S0140-6736(09)61836-5 ↗
25. http://www.abedia.com/wiley/vectors.php.
26. In vivo evaluation of a porous, elastic, biodegradable patch for reconstructive cardiac procedures10.1016/j.athoracsur.2006.06.085 ↗
27. Placement of an elastic biodegradable cardiac patch on a subacute infarcted heart leads to cellularization with early developmental cardiomyocyte characteristics10.1016/j.cardfail.2012.05.006 ↗
28. The effect of polymer degradation time on functional outcomes of temporary elastic patch support in ischemic cardiomyopathy10.1016/j.biomaterials.2013.06.020 ↗
29. Synthesis, characterization, and cytocompatibility of elastomeric, biodegradable poly (ester-urethane) ureas based on poly (caprolactone) and putrescine10.1002/jbm.10204 ↗
30. Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice10.1038/gt.2010.110 ↗
31. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector10.1128/JVI.75.24.12382-12392.2001 ↗
32. Engineering biomaterial systems to enhance viral vector gene delivery10.1038/mt.2011.111 ↗
33. Sustained viral gene delivery through core-shell fibers10.1016/j.jconrel.2009.06.007 ↗
34. Electrospun nanofibrous scaffolds for controlled release of adeno-associated viral vectors10.1016/j.actbio.2011.06.035 ↗
35. Electrospun nanofibers as versatile interfaces for efficient gene delivery
36. Coaxial electrospun fibers: applications in drug delivery and tissue engineering10.1002/wnan.1391 ↗
37. Regulated non-viral gene delivery from coaxial electrospun fiber mesh scaffolds10.1016/j.jconrel.2009.12.009 ↗
38. Core–sheath structured fibers with pDNA polyplex loadings for the optimal release profile and transfection efficiency as potential tissue engineering scaffolds10.1016/j.actbio.2011.02.031 ↗
39. Multiple release of polyplexes of plasmids VEGF and bFGF from electrospun fibrous scaffolds towards regeneration of mature blood vessels10.1016/j.actbio.2012.03.044 ↗
40. Fabrication of core-shell PEI/pBMP2-PLGA electrospun scaffold for gene delivery to periodontal ligament stem cells10.1155/2016/5385137 ↗
41. Gene delivery through cell culture substrate adsorbed DNA complexes10.1002/bit.20393 ↗
42. Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size10.1089/ten.teb.2012.0437 ↗
43. Mechanical properties and in vivo behavior of a biodegradable synthetic polymer microfiber–extracellular matrix hydrogel biohybrid scaffold10.1016/j.biomaterials.2011.01.025 ↗
44. Bi-layered polyurethane–Extracellular matrix cardiac patch improves ischemic ventricular wall remodeling in a rat model10.1016/j.biomaterials.2016.07.039 ↗
45. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat10.1089/hum.2008.123 ↗
46. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo10.1161/01.RES.0000237661.18885.f6 ↗
47. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection10.1038/mt.2008.76 ↗
48. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial10.1016/j.cardfail.2009.01.013 ↗
49. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure10.1161/CIRCULATIONAHA.111.022889 ↗
50. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure analysis of recurrent cardiovascular events and mortality10.1161/CIRCRESAHA.113.302421 ↗
51. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial10.1016/S0140-6736(16)00082-9 ↗
52. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1. SERCA2a enhances gene transfer in porcine hearts10.1038/mt.2011.268 ↗
53. Fibroblasts and myofibroblasts: what are we talking about?10.1097/FJC.0b013e3182116e39 ↗
54. Heart failure gene therapy the path to clinical practice10.1161/CIRCRESAHA.113.300269 ↗
55. A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction10.1002/jgm.1576 ↗
56. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo10.1073/pnas.90.24.11498 ↗
57. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors10.1089/hum.2005.16.235 ↗
58. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells10.1006/mthe.2001.0424 ↗
59. Development of efficient viral vectors selective for vascular smooth muscle cells10.1016/j.ymthe.2003.11.006 ↗
60. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors10.1161/01.CIR.0000109697.68832.5D ↗
61. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer10.1128/JVI.75.13.6199-6203.2001 ↗
62. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo10.1152/physiolgenomics.2000.2.3.117 ↗
63. Efficient transduction of vascular smooth muscle cells with a translational AAV2. 5 vector: a new perspective for in-stent restenosis gene therapy10.1038/gt.2013.13 ↗
64. Structural and functional characterisation of cardiac fibroblasts10.1016/j.cardiores.2004.08.020 ↗
65. Ventricular remodeling after infarction and the extracellular collagen matrix when is enough enough?10.1161/01.CIR.0000085658.98621.49 ↗
66. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts10.1016/j.brainresbull.2009.07.005 ↗
67. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy10.1089/hum.2010.005 ↗
68. In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis10.1016/j.stem.2016.05.005 ↗
69. Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction10.1038/gt.2016.20 ↗
70. Release of bioactive adeno-associated virus from fibrin scaffolds: effects of fibrin glue concentrations10.1089/ten.tea.2010.0586 ↗
71. Effective and durable genetic modification of human mesenchymal stem cells via controlled release of rAAV vectors from self-assembling peptide hydrogels with a maintained differentiation potency10.1016/j.actbio.2015.02.013 ↗
72. Lentivirus delivery by adsorption to tissue engineering scaffolds10.1002/jbm.a.32619 ↗
73. Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers10.1002/jbm.a.34449 ↗
74. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair10.1021/nn5020787 ↗
75. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer10.1161/01.CIR.0000153338.47507.83 ↗
76. Construction and analysis of compact muscle-specific promoters for AAV vectors10.1038/gt.2008.104 ↗
77. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart10.1038/nbt1073 ↗
78. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution10.1038/gt.2010.105 ↗
79. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart10.1038/ncpcardio0319 ↗